{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:10:23Z","timestamp":1678507823046},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1993,2]]},"DOI":"10.1007\/bf00873910","type":"journal-article","created":{"date-parts":[[2004,12,24]],"date-time":"2004-12-24T19:39:55Z","timestamp":1103917195000},"page":"47-51","source":"Crossref","is-referenced-by-count":4,"title":["Amonafide treatment of refractory esophageal cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"Elizabeth","family":"Poplin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel E.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00873910_CR1","first-page":"61","volume":"4","author":"MF Brana","year":"1980","unstructured":"Brana MF, Castellano JM, Roldan CM, Santos A, Vasquez D, Jimenez A: Synthesis and modes(s) of action of a new series of imide derivatives of 3-nitro-1, 8-napthalic acid. Cancer Chemother Phar 4:61\u201366, 1980","journal-title":"Cancer Chemother Phar"},{"key":"BF00873910_CR2","first-page":"1040","volume":"47","author":"BS Andersson","year":"1987","unstructured":"Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA:In vitro toxicity and DNA cleavage capacity of benzisoquinolinedione (Nafidemide: NSC 308847) in human leukemia. Cancer Res 47:1040\u20131044, 1987","journal-title":"Cancer Res"},{"key":"BF00873910_CR3","unstructured":"Clinical Brochure. Benzisoquinolinedione NSC 308847, Bethesda, MD. National Cancer Institute."},{"key":"BF00873910_CR4","first-page":"1165","volume":"71","author":"S Legha","year":"1987","unstructured":"Legha S, Ring S, Raber M, Felder T, Newman R, Krakoff I: Phase I clinical investigation of benzisoquinolinedione. CTR 71:1165\u20131169, 1987","journal-title":"CTR"},{"key":"BF00873910_CR5","first-page":"A316","volume":"10","author":"D Puccio","year":"1991","unstructured":"Puccio D, Mittelman A, Ahmed T, Coombs N, Feldman E, Nadler P, Kreis W, Molt P, Chun H, Arlin Z: Phase I trial and pharmacokinetics of amonafide. Proc ASCO 10:A316, 1991","journal-title":"Proc ASCO"},{"key":"BF00873910_CR6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.1989.7.9.1351","volume":"7","author":"R Saez","year":"1989","unstructured":"Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, Sarosy G, Von Hoff DD: Phase I clinical investigation of amonafide. Journal of Clinical Oncology 7:1351, 1989","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873910_CR7","first-page":"A1092","volume":"32","author":"SL Allen","year":"1991","unstructured":"Allen SL, Ratain M, Korzun AH, Duggan D, Nowak B, Norton L, Henderson IC: Phase II study of amonafide in previously treated metastatic breast cancer. Proc AACR 32:A1092, 1991","journal-title":"Proc AACR"},{"key":"BF00873910_CR8","first-page":"A138","volume":"10","author":"W Scheithauer","year":"1991","unstructured":"Scheithauer W, Dittrich C, Kornek G, Linkesch. W, Haider K, Depisch D: A phase II trial of amonafide in metastatic breast cancer. Proc ASCO 10:A138, 1991","journal-title":"Proc ASCO"},{"key":"BF00873910_CR9","first-page":"A584","volume":"10","author":"D Shevrin","year":"1991","unstructured":"Shevrin D, Khandekar J, Kilton L, Holder L, Showel J, Blough R, Watkins A: Amonafide in advanced hormone resistant prostate cancer: An Illinois cancer council phase II study. Proc ASCO 10:A584, 1991","journal-title":"Proc ASCO"},{"key":"BF00873910_CR10","first-page":"A573","volume":"8","author":"J Craig","year":"1989","unstructured":"Craig J, Crawford E: Phase II trial of advanced prostate cancer: A southwest oncology group study. Proc ASCO 8:A573, 1989","journal-title":"Proc ASCO"},{"key":"BF00873910_CR11","first-page":"309","volume":"8","author":"WK Evans","year":"1990","unstructured":"Evans WK, Eishenhauer EA, Cormier Y, Ayoub J, Wierzbicki R, Labeige F, Shepard FA: Phase II study of amonafide: Results of treatment and lessons from the study of an investigational agent in previously untreated patients with extensive small cell lung cancer. J Clin Oncology 8: 309\u2013395, 1990","journal-title":"J Clin Oncology"},{"key":"BF00873910_CR12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000421-199104000-00006","volume":"14","author":"MZ Burger","year":"1991","unstructured":"Burger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, DiMaggio J J, Heelan RT: Phase II trial of amonafide in patients with stage III and IV non-small cell lung cancer. Am J Clin Onc 14:124\u2013126, 1991","journal-title":"Am J Clin Onc"},{"key":"BF00873910_CR13","first-page":"A452","volume":"10","author":"K Linke","year":"1991","unstructured":"Linke K, Pazdur R, Ajani J, Abbruzzese J, Patt Y, Daugherty K, Levin B: Phase II trial of amonafide in advanced pancreatic carcinoma. Proc ASCO 10:A452, 1991","journal-title":"Proc ASCO"},{"key":"BF00873910_CR14","first-page":"A1022","volume":"10","author":"M Slavik","year":"1991","unstructured":"Slavik M, Kopecky K, Craig J, Sondak V, Samson M: Evaluation of amonafide in disseminated malignant melanom: A southwest oncology group study. Proc ASCO 10:A1022, 1991","journal-title":"Proc ASCO"},{"key":"BF00873910_CR15","first-page":"574","volume":"8","author":"CS Higano","year":"1989","unstructured":"Higano CS, Craig J, Goodman P, Blumenstein B, Wettlaufer J, Crawford ED: A phase II trial of amonafide in advanced renal cell carcinoma. Proc ASCO 8:574, 1989","journal-title":"Proc ASCO"},{"key":"BF00873910_CR16","first-page":"773","volume":"15","author":"TB Felder","year":"1987","unstructured":"Felder TB, McClean MA, Vestal ML, Luk K, Farquhar D, Legha S, Shar R, Newman RA. Pharmacokinetics and metabolism of the antitumor drug amonafide NSC 308847 in humans, drug metabolism and disposition 15:773\u2013778, 1987","journal-title":"Pharmacokinetics and metabolism of the antitumor drug amonafide NSC 308847 in humans, drug metabolism and disposition"},{"key":"BF00873910_CR17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/clpt.1991.183","volume":"50","author":"MJ Ratain","year":"1991","unstructured":"Ratain MJ, Mick R, Berezin F, Janisch L, Shilsky RL, Williams SF, Smiddy J: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clinical Pharmacology and Therapeutics 50:573\u2013579, 1991","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF00873910_CR18","first-page":"1055","volume":"31","author":"MR Grever","year":"1990","unstructured":"Grever MR, Staubus AE, Malspeis L: Correlation of Nacetylation phenotype with plasma levels of the N-acetyl- metabolite of amonafide (NSC 308847). Proc AACR 31: A1055, 1990","journal-title":"Proc AACR"},{"key":"BF00873910_CR19","first-page":"265","volume":"9","author":"H Hochster","year":"1990","unstructured":"Hochster H, Oratz R, Wernz J, Speyer J, Meyers M, Chachoua A, Walsh C, Dunleavy S, Blum R, Kreis W, Nadler P, Spigelman MK: Weekly amonafide: Phase I study of a novel schedule. Proc ASCO 9:265, 1990","journal-title":"Proc ASCO"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00873910\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T03:40:39Z","timestamp":1678506039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00873910"}},"subtitle":["A Southwest Oncology Group study"],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["BF00873910"],"URL":"https:\/\/doi.org\/10.1007\/bf00873910","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,2]]}}}